Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data

After the expiration of trastuzumab data exclusivity, biosimilar drugs were approved by regulatory agencies; among them, CT-P6 which was approved for the treatment of HER2-positive early- and advanced-breast cancer (BC) in 2018. Yet, reference trastuzumab (RTZ) is often combined with pertuzumab in e...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernat-Peguera, Adrià, Trigueros, Macedonia, Ferrando-Díez, Angélica, Ibáñez, Cristina, Bystrup, Sara, Martínez-Cardús, Anna, Margelí, Mireia, Martínez-Balibrea, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787779/
https://www.ncbi.nlm.nih.gov/pubmed/35078146
http://dx.doi.org/10.1016/j.breast.2022.01.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787779/
https://www.ncbi.nlm.nih.gov/pubmed/35078146
http://dx.doi.org/10.1016/j.breast.2022.01.007

Ejemplares similares